John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Video content above is prompted by the following questions:
Explore the logistics and best practices aimed at optimizing therapeutic response, minimizing potential adverse events, and maximizing off-treatment benefits.
How do you initiate venetoclax therapy in your practice, including titration and management of potential AEs and risk of tumor lysis syndrome?
What insights/implications do recent real-world data provide?